Neurocrine Biosciences reported second-quarter 2026 revenue of $959 million, up 39% year-over-year. The San Diego-based biopharmaceutical company raised its full-year guidance for INGREZZA to $2.825–$2.875 billion, up from $2.7–$2.8 billion. INGREZZA net product sales reached $716 million in the quarter, reflecting 15% growth. CRENESSITY sales totalled $184 million, whilst VYKAT XR contributed $54 million following the May acquisition of Soleno Therapeutics. The company completed its $2.9 billion acquisition of Soleno in May 2026, paying $53 per share in cash. Neurocrine also secured a $1 billion revolving credit facility for general corporate purposes. GAAP net income was $144 million, compared with $108 million in the prior-year period. Non-GAAP net income reached $297 million versus $166 million a year earlier.

Neurocrine Biosciences (NASDAQ:NBIX) director sells $227,512.50 in stock. July 30, 2026 Key points. * Director Leslie Norwalk sold 1,250 Neurocrine Biosciences shares for approximately $227,513 under a pre-arranged Rule 10b5-1 plan, reducing her direct holdings by 44.05% to 1,588 shares. * Neurocrine reported quarterly earnings of $2.85 per share, beating estimates of $1.66, while revenue rose 39.5% year over year to $959 million. The stock traded near its 12-month high at $185.50. * Analysts maintain a "Moderate Buy" consensus with an average price target of $194.05; institutional investors own 92.59% of the company's shares. * MarketBeat previews top five stocks to own in August. Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 1,250 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director directly owned 1,588 shares in the company, valued at approximately $289,031.88. This represents a 44.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Neurocrine Biosciences price performance. Neurocrine Biosciences stock traded up $4.71 during mid-day trading on Thursday, hitting $185.50. The company's stock had a trading volume of 2,170,803 shares, compared to its average volume of 1,182,411. The business has a 50 day moving average price of $167.01 and a 200-day moving average price of $145.90. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The stock has a market cap of $18.65 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 0.77 and a beta of 0.39. Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $2.85 EPS for the quarter, topping the consensus estimate of $1.66 by $1.19. Neurocrine Biosciences had a return on equity of 19.79% and a net margin of 21.55%.The firm had revenue of $959.00 million for the quarter, compared to the consensus estimate of $891.16 million. During the same quarter in the previous year, the business earned $1.65 earnings per share. The company's quarterly revenue was up 39.5% on a year-over-year basis. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 7.11 earnings per share for the current fiscal year. Analyst upgrades and downgrades. A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of Neurocrine Biosciences from a "buy (b-)" rating to a "buy (b)" rating in a report on Tuesday. Needham & Company LLC restated a "buy" rating and set a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. Zacks Research upgraded shares of Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, June 23rd. Leerink Partners raised their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. Finally, Guggenheim lifted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $194.05. Discover more Financial News Derivatives Institutional trading of Neurocrine Biosciences. A number of hedge funds have recently made changes to their positions in NBIX. DJE Kapital AG purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $28,000. Geneos Wealth Management Inc. grew its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Neurocrine Biosciences by 651.6% during the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company's stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. Basecamp Wealth Advisors LLC raised its position in shares of Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company's stock worth $31,000 after purchasing an additional 204 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in Neurocrine Biosciences in the 1st quarter worth about $33,000. 92.59% of the stock is owned by institutional investors. About Neurocrine Biosciences. Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research-driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities. The company's lead marketed product, Ingrezza(TM)(valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Neurocrine Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list. While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Neurocrine Biosciences names new Senior Vice Presidents. The appointments include Bret Paulson as SVP, Market Access; David Bradfute as SVP and Global Head of Intellectual Property; and Aaron Vosburgh as SVP, Finance and Accounting. July 24, 2026 Associate Editor Neurocrine Biosciences Inc., which named a new Chief Business Officer earlier this week, has appointed three Senior Vice Presidents, further strengthening its leadership team. The appointments include Bret Paulson, who joins the company as Senior Vice President, Market Access, and the promotions of David Bradfute to Senior Vice President and Global Head of Intellectual Property, and Aaron Vosburgh to Senior Vice President, Finance and Accounting. "Neurocrine is entering a new phase of growth as we expand our commercial portfolio, advance one of the industry's most productive pipelines and prepare to bring more innovative medicines to patients," said Kyle W. Gano, Ph.D., CEO, Neurocrine Biosciences. "Successfully executing on that opportunity requires exceptional leadership across every function of our company. Bret, Aaron and David each bring outstanding expertise, judgment and a proven ability to build high-performing organizations. Together, they strengthen our ability to execute today while positioning Neurocrine for the opportunities ahead, ultimately enabling us to deliver greater value for patients, healthcare providers and shareholders." Bret Paulson, SVP, Market Access. Paulson boasts nearly 30 years of experience in the biopharmaceutical and insurance industries. He will be responsible for shaping and driving Neurocrine's global market access vision, strategy and execution to provide patient access to the company's current and future medicines, while strengthening payer partnerships and reimbursement strategies across an increasingly diversified portfolio. He joins Neurocrine after more than six years at Otsuka Pharmaceutical Companies, most recently as Vice President and Head of Market Access & Channel Strategy. Prior to that, he was Area Vice President, National Accounts at Horizon after working in the commercial organizations at Schering Plough, Eli Lilly & Company, and Amgen. Paulson earned a Bachelor of Arts in Asian studies from Brigham Young University. David Bradfute, SVP and Global Head of Intellectual Property. Bradfute, who joined Neurocrine in 2017, has been promoted to Senior Vice President and Global Head of Intellectual Property and will also serve as Managing Director of Neurocrine Switzerland GmbH, based in the company's Basel, Switzerland, office. In his expanded role, Bradfute will lead the company's global intellectual property strategy and oversee the protection of Neurocrine's products, diversified portfolio, technology platforms, and scientific innovations. Before joining Neurocrine, Bradfute held leadership roles across the healthcare and life sciences industry, including a 13-year career at Arena Pharmaceuticals and later as Head of Legal and Intellectual Property at Sanford Burnham Prebys Medical Discovery Institute. He earned a bachelor's degree in biochemistry from Swarthmore College, master's and doctoral degrees in biological sciences from Stanford University, and a Juris Doctor from Stanford Law School. Aaron Vosburgh, AVP, Finance and Accounting. Vosburgh, an eight-year Neurocrine employee, will oversee enterprise financial strategy, partnering with executive leadership to align capital allocation, long-range financial planning and portfolio investments with Neurocrine's strategy to advance innovation and deliver new therapies to patients. While at Neurocrine, he has helped build, scale and strengthen the company's accounting, finance, tax, treasury, and financial planning and analysis capabilities while serving as a strategic advisor on many of the company's most important financial decisions. Prior to joining Neurocrine, Vosburgh held senior finance leadership roles at Applied Proteomics, Synthetic Genomics, Verenium Corporation, and Natural Alternatives International, following the start of his career at Ernst & Young. He is a Certified Public Accountant (inactive) and earned a Bachelor of Arts in Accounting from the University of San Diego.